How long can a person with myelodysplastic syndrome live?
Mar 22, 2022
Source: Cainiu Health
Dr. Lin Yunfei
Introduction
The life expectancy of patients with myelodysplastic syndromes (MDS) varies significantly depending on the severity of the disease, the patient’s age, and treatment response. Generally, patients in the low-risk group have a longer survival—often exceeding 10 years, and some may even achieve cure. In contrast, patients in the high-risk group have a poorer prognosis, with potential mortality within one year.
Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal disorders originating from hematopoietic stem cells, classified as malignant hematologic diseases. Their hallmark features include abnormal differentiation and maturation of myeloid cells, ineffective hematopoiesis in the bone marrow, refractory cytopenias, progressive bone marrow failure, and a high risk of transformation into acute myeloid leukemia (AML). So, how long can patients with MDS survive? The following section addresses this question.
How long can patients with myelodysplastic syndromes survive?
The actual survival duration for patients with MDS varies significantly depending on disease severity, patient age, treatment response, and other individual factors. Generally, patients in the lower-risk category have relatively longer survival—often exceeding 10 years—and some may even achieve long-term remission or functional cure. In contrast, patients in the higher-risk category typically have a poorer prognosis, with median survival often less than one year.
Management of lower-risk MDS includes supportive measures such as red blood cell transfusions, platelet transfusions, erythropoietin-stimulating agents, and granulocyte colony-stimulating factor (G-CSF). These interventions primarily aim to alleviate symptoms, correct anemia and thrombocytopenia, and manage infections—where appropriate, antibiotics may be added to effectively control infectious complications. With optimal supportive care, many lower-risk patients can maintain stable disease for extended periods.
Chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT) are generally not recommended for lower-risk patients. However, younger lower-risk patients may be considered for intensive chemotherapy followed by HSCT, which offers the potential for cure. Conversely, higher-risk MDS patients face a significantly worse prognosis and a high likelihood of progression to AML; therefore, they should be managed according to standard AML treatment protocols—including intensive chemotherapy and, when feasible, allogeneic HSCT.
The above provides an overview of survival expectations in MDS. We hope this information is helpful to you.
